Related Experiment Video
Updated: May 15, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
PCSK9 inhibitors: an updated patent review 2024-2025
Enrico Mario Alessandro Fassi1, Marco Albani1, Lorenza D'Adduzio1
1Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Milano, Italy.
Introduction:
Proprotein convertase subtilisin/kexin 9 (PCSK9) modulates the circulating levels of low-density lipoprotein cholesterol (LDL-C). Consequently, PCSK9 inhibition, at any level, from the mRNA transcription to the final interaction with LDL-R, through suitable ligands, has been established as a corroborated therapeutic strategy for fighting hypercholesterolemia, preventing the risks of cardiovascular diseases.
Area Covered:
Patent literature published between 2024 and 2025 in the Espacenet database, an international repository containing more than 150 million documents from over 100 patent‑granting authorities, focusing on disclosures claiming novel compounds designed to bind and inhibit the PCSK9 protein.
Expert Opinion:
The clinical development of small-molecule PCSK9 inhibitors, such as MK-0616 (enlicitide) and AZD0780 (laroprovstat), demonstrates that PCSK9 is still a drug target of great interest for both academic and pharmaceutical companies. Numerous patents deposited in the last two years cover compounds that are structurally related to previously deposited general structures as well as newly developed scaffolds that include quinolines and isoquinolines, peptides, pyridine, and benzothiazole derivatives. However, with mAbs and siRNAs dominating the market, small molecules are required to prove superior cost-efficiency, combination value, and cardiovascular advantages that extend beyond LDL-C reduction.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Drug Products: Biologics, Biosimilars and Interchangeables
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
FDA Approved Drugs: Changes to Approved Drugs
Modified-Release Drug Delivery Systems: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview